NuScale Power Corp reported its financial results for the first quarter of 2025, posting revenue of $13.4 million, substantially exceeding the consensus estimate of $3.44 million. Despite a sequential revenue decline of approximately 65%, the company demonstrated strong performance in the small modular reactor (SMR) sector. NuScale remains the only SMR company with design approval from the U.S. Nuclear Regulatory Commission (NRC) and is progressing toward final NRC approval to increase power output per module. Following the earnings release, BTIG raised NuScale's price target from $20 to $22 while maintaining a 'Buy' rating. An earnings call was scheduled to discuss the results in detail. Additionally, several other companies reported their first quarter 2025 financial results, including Rezolute, Healwell, 908 Devices, BrainsWay, iCAD, Hyperfine, Zevra, Spectral AI, NeuroPace, and Perimeter Medical Imaging AI, with Healwell notably reporting a 208% revenue growth, including a 224% increase in AI and data science revenue.